AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19965324 — intervention group
Group type: COMPARATOR
Intervention: Intermittent furosemide (Group 1, n=50, 1mg‐3mg/kg)
Number of subjects: 100
Study 17768273 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-nucleotide polymorphism rs6122429
Number of subjects: 316
Study 17768273 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-nucleotide polymorphism rs2236196
Number of subjects: 316
Study 15347371 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (FP, 100 microg Diskus, twice daily)
Number of subjects: 36
Study 15347371 — intervention group
Group type: COMPARATOR
Intervention: Oral montelukast (MON 10 mg, nocte)
Number of subjects: 36
Study 11573668 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow injection of 3 ml of 0.5% plain bupivacaine by infusion pump over 3 min (1 ml min(‐1))
Number of subjects: 20
Study 11573668 — intervention group
Group type: COMPARATOR
Intervention: Fast injection of 3 ml of 0.5% plain bupivacaine by hand over 10 s (18 ml min(‐1))
Number of subjects: 20
Study 11573668 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow injection group
Number of subjects: 20
Study 11573668 — intervention group
Group type: COMPARATOR
Intervention: Fast injection group
Number of subjects: 20
Study 11041533 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (ZPD, 10 mg)
Number of subjects: 0
Study 11041533 — intervention group
Group type: COMPARATOR
Intervention: Triazolam (TRZ, 0.25 mg)
Number of subjects: 0
Study 8617150 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention conditions with deviant stimuli (targets)
Number of subjects: 0
Study 8617150 — intervention group
Group type: EXPERIMENTAL
Intervention: Ignore conditions with standard stimuli omitted
Number of subjects: 0
Study 8617150 — intervention group
Group type: EXPERIMENTAL
Intervention: Counting infrequently presented 'deviants' alone (standards omitted)
Number of subjects: 0
Study 8617150 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsilateral side detection task
Number of subjects: 0
Study 1862903 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia
Number of subjects: 32
Study 1862903 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular morphine injections on demand
Number of subjects: 32
Study 6137171 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.05 mg/kg
Number of subjects: 8
Study 6137171 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.1 mg/kg
Number of subjects: 8
Study 6137171 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.2 mg/kg
Number of subjects: 8
Study 6137171 — intervention group
Group type: COMPARATOR
Intervention: Naloxone 0.015 mg/kg
Number of subjects: 8
Study 6137171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30612114 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain neuroscience education (PNE)
Number of subjects: 184
Study 30612114 — intervention group
Group type: COMPARATOR
Intervention: Traditional biomedical educational intervention
Number of subjects: 184
Study 30100532 — intervention group
Group type: EXPERIMENTAL
Intervention: 80-Hz STN-DBS
Number of subjects: 19
Study 30100532 — intervention group
Group type: EXPERIMENTAL
Intervention: 130-Hz STN-DBS
Number of subjects: 19
Study 30100532 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19
Study 26344009 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for GDM with diet, blood glucose monitoring, and insulin as needed.
Number of subjects: 95
Study 26344009 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for GDM with diet, blood glucose monitoring, and insulin as needed (nonobese women).
Number of subjects: 95
Study 26344009 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 95
Study 26344009 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group, nonobese women).
Number of subjects: 95
Study 24887209 — intervention group
Group type: EXPERIMENTAL
Intervention: ReNu MPS (solution 1)
Number of subjects: 42
Study 24887209 — intervention group
Group type: EXPERIMENTAL
Intervention: AQuify MPS (solution 2)
Number of subjects: 42
Study 24887209 — intervention group
Group type: COMPARATOR
Intervention: Comfort and dryness reporting
Number of subjects: 42
Study 23057029 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic calcium phosphate (BCP)
Number of subjects: 11
Study 23057029 — intervention group
Group type: COMPARATOR
Intervention: Deproteinized bovine bone (DBB)
Number of subjects: 11
Study 19773417 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose daclizumab (first dose: 2 mg/kg) with low-dose cyclosporine (CsA), mycophenolate mofetil (MMF), and steroids
Number of subjects: 156
Study 19773417 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (CsA, MMF, steroids)
Number of subjects: 156
Study 19773417 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose daclizumab
Number of subjects: 156
Study 19773417 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 156
Study 17921732 — intervention group
Group type: COMPARATOR
Intervention: CEOP-21 +/− rituximab
Number of subjects: 217
Study 17921732 — intervention group
Group type: EXPERIMENTAL
Intervention: CEOP-14 +/− rituximab
Number of subjects: 217
Study 17921732 — intervention group
Group type: EXPERIMENTAL
Intervention: CEOP-21/CEOP-14 with rituximab
Number of subjects: 217
Study 16151461 — intervention group
Group type: COMPARATOR
Intervention: Folic acid (400 mug daily for 5 weeks)
Number of subjects: 24
Study 16151461 — intervention group
Group type: EXPERIMENTAL
Intervention: [6S]5‐methylTHF (equimolar amounts for 5 weeks)
Number of subjects: 24
Study 12162937 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol (AT) therapy
Number of subjects: 0
Study 10402091 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil treatment for 9 weeks
Number of subjects: 21
Study 10402091 — intervention group
Group type: COMPARATOR
Intervention: Auditory and visual P300 testing
Number of subjects: 21
Study 7560584 — intervention group
Group type: EXPERIMENTAL
Intervention: Compomer restorations
Number of subjects: 0
Study 7560584 — intervention group
Group type: EXPERIMENTAL
Intervention: Compomer liners
Number of subjects: 0
Study 2147537 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (0.4 to 45 micrograms/min/100 ml forearm tissue)
Number of subjects: 8
Study 2147537 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside
Number of subjects: 8
Study 2147537 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (44.5 micrograms/min/100 ml) + Verapamil (40 micrograms/min/100 ml)
Number of subjects: 8
Study 30168635 — intervention group
Group type: EXPERIMENTAL
Intervention: KCCQ score increase by ≥5 points
Number of subjects: 2331
Study 30168635 — intervention group
Group type: EXPERIMENTAL
Intervention: KCCQ score decrease by ≥5 points
Number of subjects: 2331
Study 30168635 — intervention group
Group type: EXPERIMENTAL
Intervention: KCCQ score change by <5 points
Number of subjects: 2331
Study 30168635 — intervention group
Group type: EXPERIMENTAL
Intervention: KCCQ score decline (per 5-point decline)
Number of subjects: 2331
Study 30168635 — intervention group
Group type: EXPERIMENTAL
Intervention: KCCQ score increase (up to 8-point increase)
Number of subjects: 2331
Study 30168635 — intervention group
Group type: EXPERIMENTAL
Intervention: KCCQ score increase beyond 8 points
Number of subjects: 2331
Study 29339650 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Immunotherapy (OIT) with a daily maintenance dose of 795 mg of peanut protein
Number of subjects: 22
Study 29339650 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Immunotherapy (OIT)
Number of subjects: 22
Study 29339650 — intervention group
Group type: COMPARATOR
Intervention: Control group (historical)
Number of subjects: 22
Study 27049273 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraglottic jet oxygenation/ventilation (SJV)
Number of subjects: 49
Study 27049273 — intervention group
Group type: COMPARATOR
Intervention: Passive oxygen supply from regular nasal cannula (Control)
Number of subjects: 49
Study 25270186 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 209
Study 25270186 — intervention group
Group type: COMPARATOR
Intervention: Loxoprofen
Number of subjects: 209
Study 22794212 — intervention group
Group type: EXPERIMENTAL
Intervention: Capasio
Number of subjects: 0
Study 22794212 — intervention group
Group type: COMPARATOR
Intervention: MTA
Number of subjects: 0
Study 22794212 — intervention group
Group type: EXPERIMENTAL
Intervention: Capasio and MTA
Number of subjects: 0
Study 20369614 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with indapamide and verapamil retard
Number of subjects: 59
Study 20369614 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with indapamide and amlodipine
Number of subjects: 59
Study 17535469 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive frame valence
Number of subjects: 200
Study 17535469 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative frame valence
Number of subjects: 200
Study 17535469 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedural risk
Number of subjects: 200
Study 17535469 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal frames
Number of subjects: 200
Study 16298748 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO)
Number of subjects: 30
Study 16298748 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 30
Study 12094904 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonverbal sensitivity training group
Number of subjects: 91
Study 12094904 — intervention group
Group type: COMPARATOR
Intervention: Behavioral placebo group
Number of subjects: 91
Study 12094904 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 91
Study 12094904 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 91
Study 12094904 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient symptomatology
Number of subjects: 91
Study 10219575 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin (400 mg i.v. bolus at time of anesthesia)
Number of subjects: 860
Study 10219575 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin (2 g at induction of anesthesia and 1 g every 6 h postoperatively, i.v. bolus)
Number of subjects: 860
Study 10219575 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 860
Study 10219575 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 860
Study 7832544 — intervention group
Group type: EXPERIMENTAL
Intervention: High-function (HF) group, n=23
Number of subjects: 35
Study 7832544 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-function (LF) group, n=12
Number of subjects: 35
Study 2401060 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary angioplasty
Number of subjects: 350
Study 2401060 — intervention group
Group type: EXPERIMENTAL
Intervention: Type A stenoses
Number of subjects: 350
Study 2401060 — intervention group
Group type: EXPERIMENTAL
Intervention: Type B1 stenoses
Number of subjects: 350
Study 2401060 — intervention group
Group type: EXPERIMENTAL
Intervention: Type B2 stenoses
Number of subjects: 350
Study 2401060 — intervention group
Group type: EXPERIMENTAL
Intervention: Type C stenoses
Number of subjects: 350
Study 2401060 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus presence
Number of subjects: 350
Study 2401060 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ACC/AHA classification
Number of subjects: 350
Study 468763 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine
Number of subjects: 34
Study 468763 — intervention group
Group type: COMPARATOR
Intervention: Chlordiazepoxide
Number of subjects: 34
Study 31142526 — intervention group
Group type: EXPERIMENTAL
Intervention: Full model (age, systolic blood pressure, Glasgow Coma Scale, heart rate, respiratory rate, type of injury)
Number of subjects: 23430
Study 31142526 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple model (age, systolic blood pressure, Glasgow Coma Scale)
Number of subjects: 23430
Study 31142526 — intervention group
Group type: COMPARATOR
Intervention: CRASH-2 trial
Number of subjects: 23430
Study 31142526 — intervention group
Group type: COMPARATOR
Intervention: Northern French Alps Trauma registry
Number of subjects: 23430
Study 27754731 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele‐intervention Model and Monitoring of Families of Drug Users (TMMFDU)
Number of subjects: 325
Study 27754731 — intervention group
Group type: COMPARATOR
Intervention: Usual Treatment (UT)
Number of subjects: 325
Study 26049552 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 465
Study 26049552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 465
Study 23768273 — intervention group
Group type: COMPARATOR
Intervention: Home physical therapy (HPT)
Number of subjects: 40
Study 23768273 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy in conjunction with home physical therapy (MT-HPT)
Number of subjects: 40
Study 23768273 — intervention group
Group type: COMPARATOR
Intervention: Comparison between HPT and MT-HPT
Number of subjects: 40
Study 20393694 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative periarticular injection with local anaesthetic and adrenaline plus triamcinolone acetonide
Number of subjects: 83
Study 20393694 — intervention group
Group type: COMPARATOR
Intervention: Intra-operative periarticular injection with local anaesthetic and adrenaline
Number of subjects: 83
Study 19143771 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbachol (3 microg/kg)
Number of subjects: 12
Study 19143771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 15684287 — intervention group
Group type: EXPERIMENTAL
Intervention: bosentan
Number of subjects: 169
Study 12730341 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck Pressure (NP)
Number of subjects: 8
Study 12730341 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck Suction (NS)
Number of subjects: 8
Study 12730341 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid baroreflex (CBR) function
Number of subjects: 8
Study 10589859 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% carbohydrate (CHO) meal
Number of subjects: 6
Study 10589859 — intervention group
Group type: COMPARATOR
Intervention: 90% fat meal
Number of subjects: 6
Study 10589859 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin administration (1000 U, 500 U, and 500 U before exercise)
Number of subjects: 6
Study 10589859 — intervention group
Group type: COMPARATOR
Intervention: CHO trial
Number of subjects: 6
Study 10589859 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat trial
Number of subjects: 6
Study 8948505 — intervention group
Group type: EXPERIMENTAL
Intervention: Beraprost sodium (Dolner 40 micrograms)
Number of subjects: 0
Study 8948505 — intervention group
Group type: COMPARATOR
Intervention: Elastase (Elaszym 1800 U)
Number of subjects: 0
Study 1753158 — intervention group
Group type: EXPERIMENTAL
Intervention: 5F coronary catheters
Number of subjects: 0
Study 1753158 — intervention group
Group type: COMPARATOR
Intervention: 6F coronary catheters
Number of subjects: 0
Study 1753158 — intervention group
Group type: COMPARATOR
Intervention: 8F coronary catheters
Number of subjects: 0
Study 6805451 — intervention group
Group type: EXPERIMENTAL
Intervention: Massive-dose vitamin A therapy
Number of subjects: 0
Study 6805451 — intervention group
Group type: EXPERIMENTAL
Intervention: Correction of protein-energy malnutrition (PEM)
Number of subjects: 0
Study 6805451 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated massive vitamin A therapy
Number of subjects: 0
Study 30359789 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 184
Study 30359789 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 184
Study 28950849 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacteriophage (Pyo bacteriophage) solution for 7 days
Number of subjects: 0
Study 28950849 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution for 7 days
Number of subjects: 0
Study 28950849 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic treatment according to sensitivity pattern for 7 days
Number of subjects: 0
Study 26308643 — intervention group
Group type: EXPERIMENTAL
Intervention: Clipping
Number of subjects: 130
Study 26308643 — intervention group
Group type: COMPARATOR
Intervention: Coiling
Number of subjects: 130
Study 23179499 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported urinary incontinence
Number of subjects: 395
Study 23179499 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic pelvic organ prolapse
Number of subjects: 395
Study 23179499 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomical pelvic organ prolapse stage II-IV
Number of subjects: 395
Study 23179499 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolapse questionnaire validity
Number of subjects: 395
Study 21590473 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine 0.2 mg
Number of subjects: 84
Study 21590473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 18356448 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 mg I/kg of body weight
Number of subjects: 135
Study 18356448 — intervention group
Group type: EXPERIMENTAL
Intervention: 525 mg I/kg of body weight
Number of subjects: 135
Study 18356448 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg I/kg of body weight
Number of subjects: 135
Study 16298373 — intervention group
Group type: EXPERIMENTAL
Intervention: A1 beta-casein diet
Number of subjects: 62
Study 16298373 — intervention group
Group type: EXPERIMENTAL
Intervention: A2 beta-casein diet
Number of subjects: 62
Study 16298373 — intervention group
Group type: COMPARATOR
Intervention: Comparison of A1 and A2 diets
Number of subjects: 62
Study 14700556 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegvisomant (median dose 15 mg/day, range 10-40 mg)
Number of subjects: 16
Study 14700556 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 16
Study 14700556 — intervention group
Group type: EXPERIMENTAL
Intervention: GH receptor blockade (not specified)
Number of subjects: 16
Study 11426352 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 41
Study 11426352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 9413377 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy combined with a temporary arteriovenous fistula and anticoagulation (surgical group)
Number of subjects: 30
Study 9413377 — intervention group
Group type: COMPARATOR
Intervention: Conventional anticoagulation treatment (medical group)
Number of subjects: 30
Study 9413377 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 8435902 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose FSH (37.5 units daily, increased in 37.5 unit increments)
Number of subjects: 13
Study 8435902 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional dose FSH (75 units daily, increased in 75 unit increments)
Number of subjects: 13
Study 8435902 — intervention group
Group type: COMPARATOR
Intervention: Both protocols
Number of subjects: 13
Study 3630923 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol (0.01, 0.02, and 0.04 mg/kg, maximum total dosage 10 mg)
Number of subjects: 29
Study 3630923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 29264967 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic tablets containing Lactobacillus rhamnosus PB01, DSM 14869 and Lactobacillus curvatus EB10, DSM 32307
Number of subjects: 47
Study 29264967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 29264967 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic tablets
Number of subjects: 47
Study 27225018 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress cardiac magnetic resonance imaging (CMRI)
Number of subjects: 2000
Study 27225018 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress myocardial perfusion scintigraphy (MPS)
Number of subjects: 2000
Study 27225018 — intervention group
Group type: COMPARATOR
Intervention: CCTA followed by invasive coronary angiography (ICA) with fractional flow reserve (FFR) measurements
Number of subjects: 2000
Study 24809437 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized Mediterranean-style diet (G1: 70% breakfast, morning snack, lunch and 30% afternoon snack and dinner)
Number of subjects: 42
Study 24809437 — intervention group
Group type: COMPARATOR
Intervention: Individualized Mediterranean-style diet (G2: 55% breakfast, morning snack, lunch and 45% afternoon snack and dinner)
Number of subjects: 42
Study 21899404 — intervention group
Group type: EXPERIMENTAL
Intervention: Descriptive norm messages
Number of subjects: 0
Study 21899404 — intervention group
Group type: EXPERIMENTAL
Intervention: Health messages
Number of subjects: 0
Study 21899404 — intervention group
Group type: EXPERIMENTAL
Intervention: Appearance messages
Number of subjects: 0
Study 21899404 — intervention group
Group type: COMPARATOR
Intervention: Control messages
Number of subjects: 0
Study 21899404 — intervention group
Group type: EXPERIMENTAL
Intervention: Descriptive norm messages (university students)
Number of subjects: 0
Study 20551849 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium/vitamin D supplementation (1,000 mg of elemental calcium daily plus 400 IU of vitamin D3 daily)
Number of subjects: 754
Study 20551849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 754
Study 20551849 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium/vitamin D supplementation
Number of subjects: 754
Study 18931554 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran (100 mg/day)
Number of subjects: 24
Study 18931554 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine (40 mg/day)
Number of subjects: 24
Study 16188206 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation (4.5 g.d(‐1))
Number of subjects: 175
Study 16188206 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (OO) supplementation
Number of subjects: 175
Study 16188206 — intervention group
Group type: COMPARATOR
Intervention: Reference group (high habitual fish intake)
Number of subjects: 175
Study 12651679 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.15% plus 0.5 microg/mL of sufentanil
Number of subjects: 130